Watson Says Barr Infringes Patent For Oxytrol

Law360, New York (October 24, 2008, 12:00 AM EDT) -- Watson Laboratories Inc. has slapped generic drug manufacturer Barr Pharmaceuticals Inc. with a patent infringement lawsuit over its application to market a generic version of Oxytrol, an overactive bladder treatment.

Watson filed the lawsuit on Wednesday in the U.S. District Court of Delaware after Barr filed an abbreviated new drug application requesting approval to market and sell a generic version of Oxytrol, a skin patch that releases oxybutynin into the bloodstream to treat OAB.

In the complaint, Watson said the alleged infringement would cause “irreparable harm”...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.